Introduction
============

Cyclic vomiting syndrome (CVS), initially described in an early 19th century report,[@b1-jnm-22-643],[@b2-jnm-22-643] is characterized by random episodes of intense nausea and vomiting that can last from hours to days, interspersed with symptom-free intervals. A recent increase in review articles and CVS case reports has resulted in the 4 phases of this disorder being well described: a symptom-free interval, a prodromal phase, a vomiting phase, and a recovery phase.[@b3-jnm-22-643],[@b4-jnm-22-643]

The actual prevalence of the disease is unknown. All races, ages, and ethnicities can be affected by CVS, although Caucasians and females appear more susceptible than others.[@b4-jnm-22-643]--[@b6-jnm-22-643] A recent case report describing the illness among multiple family members suggests that the disorder may be inherited. The precise pathogenesis of CVS is unknown and likely multifactorial, but it may result from dysfunction of neuro-hormonal pathways responsible for the control of nausea and vomiting.

Symptomatic management to abort or terminate an episode is now the mainstay of treatment, with severe bouts of CVS sometimes necessitating hospitalization to address dehydration and restore homeostasis. The potential role of drugs helpful in aborting the attacks has also been well described, with the range of medications used to treat CVS -- sumatriptan, erythromycin, carnitine, propranolol, cyproheptadine, coenzyme Q10, nebivolol, tricyclic antidepressants -- thoroughly discussed.[@b7-jnm-22-643]--[@b11-jnm-22-643] However, for some drug-refractory patients, the only recourse has been sedation and a quiet environment.

No studies have been reported that examine the potential for gastric electrical stimulation (GES) as treatment for CVS. GES has been shown in clinical trials from as early as 1992 to be a safe and effective treatment option for the nausea and vomiting of drug-refractory gastroparesis (GP), with long-term studies reporting statistically significant improvement for all GP symptoms.[@b12-jnm-22-643]--[@b16-jnm-22-643] One decade-long study showed that many GP patients either remained symptom-free or continued to experience a significant reduction of symptoms with GES.[@b13-jnm-22-643]

In this pilot study, we evaluated the effectiveness of GES for treating nausea and vomiting associated with CVS.

Materials and Methods
=====================

A non-randomized, 1 year, clinical study was conducted from August 2009 to August 2010 in the Emergency Department, Clinics, and Outpatient Clinics of the University of Mississippi Medical Center. Patients were again evaluated during their follow-up visits to clinics after permanent GES (Perm GES) and were also followed up by telephone. Records from electronic chart review were obtained to collect data on hospital visits. Patients were part of a larger study of GES with the approval of the University of Mississippi Institutional Review Board.

For this pilot investigation, enrollment steps with inclusion and exclusion criteria were as follows:

Inclusion criteria:

-   Gender: male or female

-   Age range: 18 years to 70 years in age

-   Patients with CVS who met the criteria as defined by Rome III and North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN)

-   Symptoms of CVS for ≥ 1 year

-   Refractory or intolerant to antiemetic drug classes (antihistamines and phenothiazines, serotonin receptor antagonists, dopamine receptor antagonists)

-   Chronic vomiting and/or nausea with 7 or more episodes per week for either symptom irrespective of gastric emptying test (GET) values

-   The patient is willing and able to provide informed consent.

-   The patient is willing and able to return for required followup visits.

Exclusion criteria:

-   Patients \< 18 years or \> 70 years in age

-   Patients with an active infection of any kind

-   Patients with GP

-   Patients who the investigator determines are not candidates for endoscopic procedures

-   Women who are pregnant

-   Inability or unwillingness to provide informed consent

-   Unwilling or unable to return for required follow-up visits and examinations

-   Patients who are currently enrolled in another investigation of a medical device or drug

A 5-day course of temporary mucosal GES was provided,[@b13-jnm-22-643],[@b14-jnm-22-643] and for all patients, was followed by permanent stimulator implantation.[@b12-jnm-22-643]--[@b16-jnm-22-643] Symptoms occurring between initial temporary GES (Temp GES) and Perm GES placement were controlled with anti-emetics.

For Temp GES, a temporary cardiac pacing lead is endoscopically inserted as close as possible to the junction of the antrum and the body of the stomach. This temporary lead is screwed into the stomach mucosa, and 3 to 5 endoscopic clips are used to hold the lead in place. This lead is then connected to an external GES device that can be placed in a shirt pocket, telemetry pouch, etc.[@b17-jnm-22-643] For Perm GES, 2 intramuscular electrodes are inserted by laparotomy or laparoscopy into the muscularis propria of the greater curvature of the stomach roughly 10 cm proximal to the pylorus, and a neurostimulator is positioned subcutaneously in the abdominal wall. The neurostimulator is positioned subcutaneously in the abdominal wall, typically in the right midquadrant. Possible adverse effects to the procedure include infection of the neurostimulator pocket, pain related to lead perforation of the stomach, and discomfort from migration of the pulse.[@b18-jnm-22-643] Pacing of both Temp and Perm GES patients was the same as that used in GP patients (frequency, 14 Hz; intensity, 5 mA; pulse width, 330 μsec; cycle ON, 0.1 seconds; cycle OFF, 5.0 seconds).[@b17-jnm-22-643],[@b18-jnm-22-643]

Primary Outcome Measurements
----------------------------

All patients were evaluated at baseline for the primary outcome parameters associated with gastrointestinal (GI) symptoms, gastric physiology and electrophysiology, and hospital admissions. To measure GI symptoms, a standardized Likert scale PRO derived tool was used to rate nausea, vomiting, bloating, and total symptom score (0--4 each, maximum 20), as well as health-related quality of life. Health related quality of life was evaluated using the investigator-derived independent outcome measure scores (IDIOMS) assessment. Physiological assessments included Body Mass Index and the 4-hour measure of the GET. Gastric emptying was performed with the technetium labeled solid meal measured for 4 hours.[@b19-jnm-22-643] Hospital admissions prior to GES treatment were also determined at the baseline evaluation ([Table 1](#t1-jnm-22-643){ref-type="table"}).

At day 1 (GES ON) and day 5 (GES OFF) of Temp GES, symptom and quality-of-life measures were again obtained, as were the body mass index (BMI) and the 4-hour measure of the GET. Post permanent stimulator placement, symptom and quality of life measures were again collected, along with the BMI and the 4-hour measure of the GET. Cutaneous electrograms as well as mucosal electrograms were obtained at baseline and post-Temp GES. Serosal electrograms were also obtained at the time of Perm GES placement ([Table 2](#t2-jnm-22-643){ref-type="table"} and [Fig. 1](#f1-jnm-22-643){ref-type="fig"}).

Changes in vomiting scores, total symptom scores, cutaneous electrogram, mucosal electrograms, and 4-hour GET were assessed. Hospital admissions per year were assessed at baseline, at Temp GES, and after Perm GES implantation. Follow-up assessments were conducted at 1-year following Perm GES implantation, with patients presenting back to clinic or over the phone. Findings for the primary parameters, as measured at baseline and post temporary and permanent treatment, were compared by paired *t* tests and reported as mean ± SD.

Results
=======

A total of 11 consecutive patients (4 white and 3 black males, 4 white females; mean age 38 years; 5 patients with concomitant glucose intolerance), all meeting the Rome III criteria[@b20-jnm-22-643] and NASP-GHAN consensus for drug refractory CVS,[@b21-jnm-22-643] were included in our study. Baseline characteristics and motility measures can be seen in [Table 3](#t3-jnm-22-643){ref-type="table"}.

Patients were followed after initial Temp GES, which resulted in improvement in nausea and vomiting. These findings were significant and led to Perm GES placement. Patients with CVS treated with GES showed significant improvement in their nausea, vomiting, total symptom scores, and number of hospitalizations. Vomiting episodes decreased by 83 percent and 69 percent after both Temp and Perm GES, respectively. Nausea decreased by 62 percent and 46 percent after both Temp and Perm GES, respectively.

The mean symptom scores for the 5 upper GI symptoms associated with CVS, gastric emptying times, and the health related quality of life IDIOMS values at baseline, during Temp GES, and after permanent stimulator implantation for the 11 CVS patients treated with GES, are provided in [Table 4](#t4-jnm-22-643){ref-type="table"}.

With temporary stimulation, nausea was reduced from the mean baseline score of 3.55 to 1.35 (62% reduction), while vomiting was significantly reduced from a mean of 2.7 to 0.45 (83% reduction). Bloating, early satiety, and total symptom scores were also significantly reduced ([Table 4](#t4-jnm-22-643){ref-type="table"}). Total symptom scores also showed a reduction from a baseline score of 14.05 (± 3.23) to 4.5 (± 4.35), indicating a 68% significant reduction after temporary stimulation.

Permanent stimulation resulted in a reduced mean score of 1.9 (46% reduction) for nausea from baseline values. There were no significant relationships in our small patient sample for gastric emptying times ([Table 5](#t5-jnm-22-643){ref-type="table"}), although a significant improvement was seen after both temporary and permanent stimulator implantation for IDIOMS quality of life measures ([Table 4](#t4-jnm-22-643){ref-type="table"}). In addition, the total symptom score was reduced to 8.42 (± 5.92), a 40% improvement when compared to a baseline value of 14.05 (± 3.23).

Vomiting episodes fell from 2.68 (± 1.27) to 0.83 (± 1.6), indicating a significant improvement with permanent stimulation (69% reduction) ([Table 4](#t4-jnm-22-643){ref-type="table"} and [Fig. 2](#f2-jnm-22-643){ref-type="fig"}). Improvement in vomiting and hospitalization events is also seen at 1-year follow-up after Perm GES therapy. Hospitalizations decreased from 9.14 (± 7.21) annual admissions prior to Perm GES to 1.5 (± 1) annual admissions thereafter ([Table 1](#t1-jnm-22-643){ref-type="table"}). The number of hospital admissions due to vomiting also significantly decreased from 6.19 (± 2.52) to 2.25 (± 1.5) after permanent stimulation.

Cutaneous and mucosal electrogram frequencies also changed after temporary electrical stimulation, with the results of electrogastrogram (EGG) and electrogram values for baseline, temporary, and permanent recordings are shown in [Table 2](#t2-jnm-22-643){ref-type="table"} and [Figure 1](#f1-jnm-22-643){ref-type="fig"}. Baseline cutaneous EGG had a mean frequency of 6.69 (± 4.57) and mean amplitude of 0.12 (± 0.07). After Temp GES there was an insignificant reduction in mean frequency, 5.72 (± 1.82), and amplitude, 0.12 (± 0.09). Further reductions in cutaneous EGG were also seen in frequency, 4.98 (± 2.21), and amplitude, 0.12 (± 0.06), though clinically insignificant. Serosal EGG measurements taken at baseline had a mean frequency of 5.81 (± 2.32) and amplitude of 0.53 (± 1.09). Measurements after Temp GES showed a clinically insignificant reduction in frequency, 4.64 (± 1.55), and amplitude, 0.32 (± 0.37) ([Table 2](#t2-jnm-22-643){ref-type="table"}).

Discussion
==========

The key to the treatment of CVS is its early recognition. Moreover, long-term management of the disorder requires an engaged and responsive collaboration among the doctor(s), patient, and family involved in care, and is ideally treated through the structure of a patient centered medical home. Updated electronic records that can provide access to a patient's stereotypical experiences of CVS, as well as indicate triggers that have pre-disposed the patient to attacks, are particularly useful in an illness that often goes unrecognized and for which emergency departments routinely provide initial treatment. For patients with drug-refractory CVS, however, lessening the impact of the disorder on quality of life may require gastroenterological intervention.

Patients in our pilot study benefitted from both temporary and permanent GES, showing a significant decrease in nausea and vomiting as evidenced by the decreases in symptoms scores seen in [Table 4](#t4-jnm-22-643){ref-type="table"}. Our findings demonstrate a 62% reduction in nausea symptoms from baseline and a concurrent 83% reduction in vomiting after temporary stimulation. With permanent GES, nausea and vomiting were decreased by 46% and 69%, respectively. Total symptom scores also significantly decreased from baseline by 68% and 40% after Temp GES and Perm GES, respectively. At one-year follow-up after Perm GES implantation, these patients continued to show significant symptom reduction and decreased number of hospital admissions. Patients' quality of life also improved IDIOMS significantly. There is a possibility that patients' symptoms could have improved without any intervention once their cyclical phase was over, but a significant improvement in hospital admissions after implantation of a Perm GES device was also observed. Patients' burden on healthcare showed improvement with a 66% and 84% reduction in hospital admission days from baseline after Temp GES and Perm GES, respectively. In addition, hospital admissions due to vomiting showed a 47% and 64% reduction after Temp GES and Perm GES, respectively, when compared to baseline values. Thus, given this limited data, we believe that GES provides medically refractory patients with an effective option for relief of this debilitating disease.

Researchers at another center have suggested that GET may be normal or rapid in patients with CVS;[@b19-jnm-22-643],[@b22-jnm-22-643],[@b23-jnm-22-643] we observed only that GET showed small improvement after permanent device placement. We believe that acute CVS, which in these patients is sometimes called coalescent CVS, behaves like GP and shares similar pathophysiology.[@b24-jnm-22-643]

We will continue to follow our patient cohort's progress long term to learn about the effects of GES on CVS. However, our pilot study results support the use of GES as a treatment option for medically refractory CVS.

Limitations to this study include small sample size, lack of control subjects, non-randomized study, racial differences not included in the data analysis, and recall bias affecting follow up studies. This pilot study was conducted among only 11 patients, so that all results must be seen as preliminary findings. It is also pertinent to note that symptomatic relief from CVS may be secondary to a placebo effect.

In conclusion, GES shows promise as a viable therapeutic option for individuals suffering from drug refractory CVS. Our study demonstrates the potential benefits not only in the patients' quality of life, but also in the overall hospital costs and healthcare burden. Future studies to better understand the pathophysiology of CVS are needed to guide future treatment protocols. In addition, more studies on a larger scale are needed to determine the mechanisms by which GES may exert an effect on CVS. An increase in awareness among physicians in diagnosing CVS, basic science, and clinical research in CVS will hopefully lead to better patient outcomes.
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![Changes in mucosal frequency vs pre-temporary gastric electrical stimulation (Pre-tGES; baseline) mucosal frequency at temporary GES treatment initiation. Pre stimulation frequency = 4.72, post stimulation frequency = 4.54, slope = −1.02 (−1.68, −0.37), *P* = 0.009, R^2^ = 0.71.](jnm-22-643f1){#f1-jnm-22-643}

![Average change in vomiting scores before and after temporary gastric electrical stimulation (GES). Significant improvements were seen in vomiting scores for all patients with treatment with temporary GES. An average decrease in vomiting score by −2.24 units (−3.18, −1.29) was observed during our study at the end of a 5-day trial with temporary GES.](jnm-22-643f2){#f2-jnm-22-643}

###### 

Comparison of Burden on Health Care with Gastric Electrical Stimulation Therapy in Cyclic Vomiting Syndrome Patients

                                         Baseline      Temp GES      *P*-value   Perm GES     *P*-value
  -------------------------------------- ------------- ------------- ----------- ------------ -----------
  Number of hospital admission days      9.14 ± 7.21   5.0 ± 5.23    0.344       1.5 ± 1.0    0.069
  Number of admissions due to vomiting   6.19 ± 2.52   3.25 ± 3.38   0.118       2.25 ± 1.5   0.018

Temp GES, temporary gastric electrical stimulation; Perm GES, permanent GES.

###### 

Comparison of Electrogastrogram with Gastric Electrical Stimulation Therapy in Cyclic Vomiting Syndrome Patients

                                                  Baseline      Temp GES      *P*-value   Perm GES      *P*-value
  ----------------------------- ----------------- ------------- ------------- ----------- ------------- -----------
  Mucosal electrogastrogram     Frequency (cpm)   5.81 ± 2.32   4.64 ± 1.55   0.233       \-            \-
                                Amplitude (μV)    0.53 ± 1.09   0.32 ± 0.37   0.602       \-            \-
  Cutaneous electrogastrogram   Frequency (cpm)   6.69 ± 4.57   5.72 ± 1.82   0.584       4.98 ± 2.21   0.498
                                Amplitude (μV)    0.12 ± 0.07   0.12 ± 0.09   0.904       0.12 ± 0.06   0.979

Gastric mucosal electrogram performed only during temporary gastric electrical stimulation (Temp GES) implantation.

Perm GES, permanent GES.

###### 

Demographic Information and Baseline Motility Measures in Patients with Cyclic Vomiting Syndrome[a](#tfn4-jnm-22-643){ref-type="table-fn"}

  Variable                 Mean     ± SD
  ------------------------ -------- -------
  Age                      37.64    14.92
  Male                     64.00%   0.50
  Diabetics                45.00%   0.52
  White                    73.00%   0.47
  BMI                      28.96    6.99
  Nausea                   3.55     0.69
  Vomiting                 2.68     1.27
  Bloating                 2.36     1.52
  Abdominal pain           2.91     1.20
  Anorexia/early satiety   2.55     1.44
  Total symptom score      14.05    3.23
  GET 1 hr                 63.30    31.81
  GET 2 hr                 41.30    28.99
  GET 4 hr                 19.90    18.08
  GET total                119.44   4.34

The mean symptom scores for the 5 upper gastrointestinal symptoms associated with cyclic vomiting syndrome (CVS), gastric emptying times, and investigator-derived independent outcome measure scores values at baseline, during temporary mucosal gastric electrical stimulation, and after permanent stimulator implantation for the 11 CVS patients treated with gastric electrical stimulation.

BMI, body mass index; GET, gastric emptying test.

###### 

Comparison of Gastrointestinal Symptoms with Gastric Electrical Stimulation Therapy in Cyclic Vomiting Syndrome Patients

                           Baseline       Temp GES       *P*-value   Perm GES       *P*-value
  ------------------------ -------------- -------------- ----------- -------------- -----------
  Nausea                   3.55 ± 0.69    1.35 ± 1.70    0.001       1.91 ± 1.11    0.002
  Vomiting                 2.68 ± 1.27    0.45 ± 1.26    0.001       0.83 ± 1.60    0.019
  Bloating                 2.36 ± 1.52    0.8 ± 1.32     0.021       1.17 ± 1.60    0.148
  Anorexia/early satiety   2.55 ± 1.44    0.65 ± 1.11    0.017       1.83 ± 1.37    0.337
  Abdominal pain           2.90 ± 1.20    1.35 ± 1.53    0.003       2.67 ± 1.17    0.694
  Total symptom score      14.05 ± 3.23   4.5 ± 4.35     0.001       8.42 ± 5.92    0.021
  IDIOMS score (0--30)     20.0 ± 4.22    14.45 ± 4.55   0.003       15.22 ± 5.12   0.006

Temp GES, temporary gastric electrical stimulation; Perm GES, permanent GES; IDIOMS, investigator-derived independent outcome measure scores.

###### 

Comparison of Gastric Motility Measures with Gastric Electrical Stimulation Therapy in Cyclic Vomiting Syndrome Patients[a](#tfn7-jnm-22-643){ref-type="table-fn"}

             Baseline        Temp GES        *P*-value   Perm GES        *P*-value
  ---------- --------------- --------------- ----------- --------------- -----------
  GET 1 hr   63.3 ± 31.81    76.74 ± 21.85   0.269       51.28 ± 33.90   0.542
  GET 2 hr   41.30 ± 28.99   49.87 ± 29.99   0.524       30.08 ± 24.90   0.511
  GET 4 hr   19.90 ± 18.08   28.93 ± 30.09   0.433       6.99 ± 13.98    0.470

Mean gastric emptying test (GET) activity at baseline, post temporary gastric electrical stimulation (Temp GES), and post permanent GES (Perm GES) in patients with cyclic vomiting syndrome measured in %.
